156755-37-2

Basic information

• Product Name: BenzeneMethanol, 3-[(1R)-3-[bis(1-Methylethyl)aMino]-1-phenylpropyl]-4-(phenylMethoxy)-
• Synonyms: BenzeneMethanol, 3-[(1R)-3-[bis(1-Methylethyl)aMino]-1-phenylpropyl]-4-(phenylMethoxy)-;(R)-(4-(benzyloxy)-3-(3-(diisopropylaMino)-1-phenylpropyl)phenyl)Methanol;O-Des(2-Methylpropan-1-one)-O-Benzyl-Fesoteridone;3-[(1R)-3-[Bis(1-methylethyl)amino]-1-phenylpropyl]-4-(phenylmethoxy)benzenemethanol
• CAS NO: 156755-37-2
• Molecular Formula: C₂₉H₃₇NO₂
• Molecular Weight: 431.60958
• Mol File: 156755-37-2.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• CAS DataBase Reference: BenzeneMethanol, 3-[(1R)-3-[bis(1-Methylethyl)aMino]-1-phenylpropyl]-4-(phenylMethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: BenzeneMethanol, 3-[(1R)-3-[bis(1-Methylethyl)aMino]-1-phenylpropyl]-4-(phenylMethoxy)-(156755-37-2)
• EPA Substance Registry System: BenzeneMethanol, 3-[(1R)-3-[bis(1-Methylethyl)aMino]-1-phenylpropyl]-4-(phenylMethoxy)-(156755-37-2)

Safety Data

• Hazardous Substances Data: 156755-37-2(Hazardous Substances Data)

Usage

Uses

O-Des(2-Methylpropan-1-one)-O-Benzyl-Fesoteridone is an impurity in the synthesis of Fesoteridone (F321300), a muscarinic receptor antagonist for the treatment of Lower Urininary Tract Symptoms (LUTS).

Upstream product

• 156755-35-0 methyl 4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]benzoate 
• 140-10-3 (E)-3-phenylacrylic acid 
• 106-41-2 4-bromo-phenol 
• 156755-23-6 6-bromo-4-phenyl-3,4-dihydro-2H-chromen-2-one 
• 156755-24-7 methyl 3-[2-(benzyloxy)-5-bromophenyl]-3-phenylpropanoate 
• 250214-37-0 (+/-)-toluene-4-sulphonic acid 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl ester 
• 156755-33-8 (R)-4-(benzyloxy)-3-(3-(diisopropylamino)-1-phenylpropyl)benzoic acid hydrochloride 
• 1135493-18-3 C₂₀H₁₈O₈*C₂₈H₃₄BrNO 
• 848768-06-9 (R)-3-[2-(benzyloxy)-5-methylphenyl]-N,N-diisopropyl-3-phenylpropan-1-amine 
• 214601-54-4 (R)-[4-benzyloxy-3-(3-diisopropylamino-1-phenyl-propyl)-phenyl]-methanal 
• 1402604-30-1 benzyl desfesoterodine fumarate 
• 209747-05-7 (S)-2-[3-[bis-(1-methylethyl)-amino]-1-phenylpropyl]-4-methylphenol tartrate 
• 854306-67-5 methyl 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropionate 
• 40546-94-9 6-methyl-4-phenyl-3,4-dihydrocoumarin 

Downstream Products

• 207679-81-0 (R)-2-[3-(diisopropylamino)-1-phenylpropyl]-4-(hydroxymethyl)-phenol 
• 286930-02-7 fesoterodine 
• 286930-03-8 fesoterodine fumarate 
• 286930-03-8 fesoterodine fumarate 
• 156755-20-3 PNU 200577 l-mandelate salt 
• 1390644-34-4 isobutyric acid 2-((R)-3-diisopropylammonium-1-phenyIpropyl)-4-(hydroxymethyl)phenyl ester (R)-acetoxy(phenyl)acetate 
• 1390644-38-8 (R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxylmethyl)phenylmethacrylate mandelate 
• 1390644-37-7 (R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxylmethyl)phenyl methacrylate 
• 1390644-50-4 (R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenyl-2-bromo-2-methyl propanoate 
• 1390644-52-6 2-((R)-3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyi)phenyl-3-bromo-2-methyl propanoate 
• 286930-03-8 2-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate fumarate 

Relevant articles and documents

Ligand-Phospholipid Conjugation: A Versatile Strategy for Developing Long-Acting Ligands That Bind to Membrane Proteins by Restricting the Subcellular Localization of the Ligand

We hypothesized that if drug localization can be restricted to a particular subcellular domain where their target proteins reside, the drugs could bind to their target proteins without being metabolized and/or excreted, which would significantly extend the half-life of the corresponding drug-target complex. Thus, we designed ligand-phospholipid conjugates in which the ligand is conjugated with a phospholipid through a polyethylene glycol linker to restrict the subcellular localization of the ligand in the vicinity of the lipid bilayer. Here, we present the design, synthesis, pharmacological activity, and binding mode analysis of ligand-phospholipid conjugates with muscarinic acetylcholine receptors as the target proteins. These results demonstrate that ligand-phospholipid conjugation can be a versatile strategy for developing long-acting ligands that bind to membrane proteins in drug discovery.

PROCESS FOR THE PREPARATION OF FESOTERODINE

The present invention relates to an improved process for the preparation of Fesoterodine and pharmaceutically acceptable salts thereof. The present invention particularly relates to a process for the preparation of Fesoterodine from O-benzyl tolterodine.

DESFESOTERODINE SALTS

The invention relates to substantially pure Desfesoterodine salts, Desfesoterodine salts, solid state forms thereof and pharmaceutical compositions comprising one or more of the Desfesoterodine salts and/or solid state forms thereof.